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Aminoglycoside-induced cochlear ototoxicity causes hair cell (HC) loss and results in
hearing impairment in patients. Previous studies have developed the concept of an
ototoxicity-sensitive period during which the cochleae of young mice are more vulnerable
to auditory trauma than adults. Here, we compared neomycin-induced ototoxicity at the
following four developmental ages in mice: postnatal day (P)1–P7, P8–P14, P15–P21,
and P60–P66. We found that when neomycin was administered between P8 and P14,
the auditory brainstem response threshold increase was significantly higher at low
frequencies and HC loss was significantly greater in the apical turn of the cochlea
compared to neomycin administration during the other age ranges. Quantitative real-time
PCR (qPCR) data revealed that the expression of apoptotic markers, including Casp3 and
Casp9, was significantly higher when neomycin was injected from P8 to P14, while the
expression of the X-linked inhibitor of apoptosis protein (XIAP) gene was significantly
higher when neomycin was injected from P60 to P66. Because XIAP expression was
low during the neomycin-sensitive period, we overexpressed XIAP in mice and found that
it could protect against neomycin-induced hearing loss at low frequencies and HC loss in
the apical turn of the cochlea. Altogether, our findings demonstrate a protective role for
XIAP against neomycin-induced hearing loss and HC loss in the apical turn of the cochlea
during the ototoxic-sensitive period, and suggest that apoptotic factors mediate the effect
of neomycin during the ototoxic-sensitive period.
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INTRODUCTION
Aminoglycosides can be ototoxic when administered to adults,
children, and infants. It has been reported that the incidence
of aminoglycoside-induced cochlear ototoxicity in neonates is
greater than that in adults. In addition, the risk of ototoxic-
ity is higher in preterm neonates than in full-term neonates
(Henley and Rybak, 1993). The concept of an ototoxicity-
sensitive period was first proposed in the 1980s (Chen and
Aberdeen, 1981; Chen and Saunders, 1983; Eggermont, 1986) as
a time period during which the cochleae of young animals are
Abbreviations: HC, hair cell; P, postnatal day;WT, wild type; ABR, auditory brain-
stem response; XIAP, X-linked inhibitor of apoptosis protein; IAP, inhibitor of
apoptosis protein; Xaf1, XIAP-associated factor 1; AIF, apoptosis-inducing factor;
BIR, baculoviral IAP repeat.
more vulnerable to auditory traumas (Eggermont, 1986; Henley
and Rybak, 1995; Henley et al., 1996). However, the mecha-
nisms involved in the ototoxicity-sensitive period are not well
understood.
Several hypotheses have been proposed to describe the hyper-
sensitivity of neonates to ototoxic drugs, and caspase-mediated
apoptosis is a common theme (Forge and Li, 2000; Matsui
et al., 2002). As one of the primary apoptosis executioner
molecules (Ashkenazi and Dixit, 1998; Debatin and Krammer,
2004; Jiang and Wang, 2004; Salvesen and Riedl, 2008), caspase-3
has been widely used to assess the apoptosis of hair cells (HCs)
in aminoglycoside-induced ototoxicity (Forge, 1985; Nakagawa
et al., 1997; Cunningham et al., 2002; Wei et al., 2005; Tabuchi
et al., 2007). Thus, caspase inhibition as a method to prevent
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cochlear HC death might be a useful treatment strategy for
aminoglycoside-induced ototoxicity.
Inhibitor of apoptosis protein (IAP) prevents apoptosis by
blocking the classic caspase-mediated apoptotic cascade and the
JNK pathway. X-linked inhibitor of apoptosis protein (XIAP) is
the most potent IAP and is a broad-range suppressor of apopto-
sis that functions by directly inhibiting caspases (Deveraux and
Reed, 1999; Deveraux et al., 1999). XIAP is broadly expressed in
all human tissues except peripheral blood leukocytes, and XIAP
overexpression increases the survival of many cell types upon
exposure to a variety of apoptotic triggers (Emamaullee et al.,
2005; Zhu et al., 2007; Hu et al., 2010; Plesner et al., 2010; Wang
et al., 2010, 2011; Unsain et al., 2013).
In this study, we first compared neomycin-induced hearing
loss and HC loss at different developmental stages in mice. We
then measured the expression levels of apoptosis-related genes
in response to neomycin administration in mice at different
developmental stages. Finally, we used XIAP overexpression mice
to investigate the mechanisms through which XIAP and down-
stream apoptotic factors affect neomycin-induced ototoxicity
during the sensitive period.
MATERIALS AND METHODS
MOUSE MODELS AND TREATMENTS
Transgenic mice overexpressing XIAP (Wang et al., 2010, 2011)
were kind gifts from Dr. Robert G. Korneluk at the Children’s
Hospital of Eastern Ontario Research Institute (Ottawa, Ontario,
Canada). Experiments were performed in C57BL/6J wild-type
(WT) mice and in XIAP overexpression mice (Experimental
Animal Center, Shanghai Medical College of Fudan University,
China). Postnatal day (P)0 was defined as the day of birth. Mice
received a daily subcutaneous injection of neomycin (200mg/kg)
or sterile saline for 7 days. All animal procedures were per-
formed according to protocols approved by the Animal Care and
Use Committee of Fudan University and were consistent with
the National Institutes of Health Guide for the Care and Use
of Laboratory Animals. All efforts were made to minimize the
number of animals used and prevent their suffering.
AUDITORY BRAINSTEM RESPONSE (ABR) TEST
The hearing thresholds of the mice were examined with the
ABR test. In this test, changes in the electrical activity of the
brain in response to sound were recorded via electrodes that
were placed on the scalp of the mice. Animals were anesthetized
with ketamine (100mg/kg) and xylazine (25mg/kg) and placed
on a thermostatic heating pad in a sound-attenuating cham-
ber to maintain their body temperatures at 38◦C. Frequency-
specific auditory responses weremeasured using the Tucker-Davis
Technology system (TDT System III, Alachua, FL, USA) as previ-
ously described (Wang et al., 2010). All ABR tests were performed
on mice older than P21.
TISSUE PREPARATION
After sacrificing the mice, the right otic capsule was immediately
isolated, rapidly frozen in liquid nitrogen, and stored at −70◦C
until further processing. To obtain the total RNA and protein
extract, 10 cochleae were pooled in ice-cold buffer and processed
with the Qiagen AllPrep® DNA/RNA/Protein Mini kit follow-
ing the manufacturer’s instructions. The RNA concentration was
measured with a Bio-Rad spectrophotometer. Complementary
(c)DNA was synthesized from 1μg total RNA by reverse tran-
scription using random primers (Promega) and Superscript III
reverse transcriptase (Life Technologies, Foster City, CA, USA)
following the manufacturer’s protocols. Quantitative real-time
PCR (qPCR) was performed using SYBR Green PCR Master Mix
(Life Technologies) on a Bio-Rad IQ5Detection System (Bio-Rad,
USA). Primer sequences are listed in Table 1. The left temporal
bones were collected and stored overnight in 4% paraformalde-
hyde before decalcification in EDTA [4% in phosphate-buffered
saline (PBS), pH = 6.4] for a total of 72 h. The otic capsule was
then removed, and the cochlea was carefully isolated from the
surrounding bony tissue. The organ of Corti was separated and
immediately processed for immunofluorescent staining.
IMMUNOFLUORESCENCE
After fixation, cochlear samples were blocked with 10% normal
donkey serum in 10mM PBS (pH 7.4) with 0.3% Triton-X100
for 1 h at room temperature (RT) and then incubated with pri-
mary antibody overnight at 4◦C. The next day the tissues were
incubated for 2 h at 4◦C with 488- or 594-conjugated donkey sec-
ondary antibody (1:500 dilution, Invitrogen) and 4,6-diamidino-
2-phenylindole (DAPI, 1:800 dilution, Sigma-Aldrich). Omission
of primary antibody served as the negative control. The follow-
ing primary antibodies were used: anti-myosin VIIA (myo7a)
(1:500 dilution, cat. #25-6790 Proteus BioSciences), and anti-
cleaved caspase-3 (1:1000 dilution, cat. #9579S, Cell Signaling
Technology).
Cochleae were dissected into apical, middle, and basal turns
and images were taken using a Leica SP5 confocal fluorescence
microscope (Leica, Germany).
Table 1 | PCR primer sequences used in the experiments.
Gene Forward sequence Reverse sequence
Xiap NM 009688 5′-TTCCCAAATTCAACAAACTCTCCA-3′ 5′-ACTTCACTTTATCGCCTTCACCTA-3′
Diablo NM023232 5′-CTGGGGGCCCTGGGGTCCTA-3′ 5′-GAAAACTGGTCCCTGGTGGTCA-3′
Xaf1 NM001037713 5′-CTGCCTGCGCTTCATAGTCCTT-3′ 5′-TGCACGGCCAGCTCACAGAAC-3′
Htra2 NM 019752 5′-AGTAGGGCGGGCGAGGAGAGT-3′ 5′-AGCAGAGCCCGGAGGTCAGG-3′
Casp3 NM009810 5′-CGGGGTACGGAGCTGGACTGT-3′ 5′-ATGCTGCAAAGGGACTGGATGAAC-3′
Casp 9 NM 015733 5′-AGGCCCGTGGACATTGGTTCT-3′ 5′-AGTTGGAGCCCGTGCGTGTG-3′
β-actin NM_007393.3 5′-TGACGGCCAGGTCATCACTA-3′ 5′-ACGGATGTCAACGTCACACTTC-3′
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CELL COUNTS
For HC quantification in the neomycin-treated samples, we
imaged the entire cochlea using a 63× objective and counted
the myo7a+ HCs that remained. The same procedure was used
to quantify caspase-3+ and caspase-3+/myo7a+ cells. For all
experiments, only one cochlea from each mouse was used for
immunofluorescence and quantification. Thus, n represents the
number of mice examined.
STATISTICAL ANALYSES
Data were expressed asmean± SD. ABR thresholds were analyzed
by a two-way ANOVA followed by a Newman–Keuls post-hoc test.
Immunofluorescence analysis was performed with a two-tailed,
unpaired Student’s t-test when comparing two groups or with
a one-way ANOVA followed by a Dunnett’s multiple compar-
isons test when comparing more than two groups. p < 0.05 was
considered statistically significant.
RESULTS
NEOMYCIN TREATMENT AT DIFFERENT STAGES INDUCED DIFFERENT
LEVELS OF HEARING LOSS
Aminoglycoside-induced cochlear toxicity in neonatal mice is
greater than that in adults (Chen and Aberdeen, 1981; Chen and
Saunders, 1983). Here we divided the WT mice into four groups
for daily subcutaneous injections of neomycin (200mg/kg) or
saline. Group 1 was injected from P1 to P7, Group 2 was injected
from P8 to P14, Group 3 was injected from P15 to P21, and
Group 4 was injected from P60 to P66. We measured hearing
function using pure tone ABR thresholds in the neomycin-treated
and control mice 2 weeks after the last injection. At low fre-
quencies, such as 8 kHz and 16 kHz, ABR thresholds were signif-
icantly increased in neomycin-treated mice compared to controls
for Groups 2 and 3 (p < 0.01 for both frequencies and both
groups; n = 6–7). However there was no significant difference
between the neomycin-treated mice and controls for Groups 1
and 4 (p = 0.194 and p = 0.056 for 8 and 16 kHz, respectively,
in Group 1 and p = 0.218 and p = 0.145, respectively, in Group
4; n = 6–7 mice). At high frequencies, such as 24 and 32 kHz,
ABR thresholds were significantly increased in all four groups
of neomycin-treated mice compared to controls (p < 0.01,
n = 6–7) (Figures 1A1–A4). Among all four groups, the increase
in hearing thresholds in the neomycin-treated mice compared
to controls was greatest in Group 2. At 8 kHz, the ABR thresh-
olds in Group 2 increased significantly more than any other
group (p < 0.01, n = 6–7); at 16 kHz, Groups 2 and 3 increased
more than the other two groups (p < 0.01 for both groups,
n = 6–7); and at 24 kHz and 32 kHz, Groups 1–3 increased more
than Group 4 (p < 0.01, n = 6–7)(Figure 1B).
NEOMYCIN TREATMENT AT DIFFERENT STAGES INDUCED DIFFERENT
LEVELS OF HC LOSS
To further investigate the neomycin-induced ototoxicity in the
four groups, HC loss in all three turns of the cochlea was eval-
uated in 3–5 cochleae from each group. Samples were compared
2 weeks after the last injection of neomycin or saline (Figure 2).
We found that the number of remaining HCs in Group 2 was sig-
nificantly lower in all three turns compared to all other groups
(p < 0.01, n = 3–5). In the apical turn, there was no significant
difference in the number of remaining HCs among Groups 1, 4,
and saline controls (n = 3–5). In the middle and basal turns, the
number of remaining HCs in Groups 2 and 3 was significantly
lower than Groups 1, 4, and saline controls (p < 0.01 for both
groups, n = 3–5). In the basal turn, the number of remaining
HCs in Groups 1 and 4 were significantly lower than the saline
control group (p < 0.01 for both groups, n = 3–5) (Figure 2B).
These results showed that Groups 2 and 3 had significant HC
loss in the apical turn—while the other groups had no significant
HC loss—and that Group 2 in particular had significantly more
HC loss in the middle and basal turns than all other groups. This
also suggests that HC loss in the apical turn of Group 2 was caused
by the hypersensitivity to neomycin-induced ototoxicity during
the sensitive period.
GENE EXPRESSION LEVELS OF APOPTOSIS FACTORS WERE DIFFERENT
WHEN NEOMYCIN TREATMENT OCCURRED AT DIFFERENT AGES
To further understand the mechanism resulting in the sensi-
tive period for neomycin-induced ototoxicity, we investigated the
gene expression of apoptosis-related genes by qPCR. In this set of
experiments, we divided the WT mice into four groups as above
and the mice were injected with neomycin or saline for 7 days
and sacrificed 3 days after the last injection. The day of sacrifice
was determined by cleaved-caspase-3 expression in the cochlea as
shown by the immunofluorescence in Figure S1A. The number
of caspase-3+ cells reached its peak at 3 days after the last injec-
tion (Figure 4B1). Because the ABR andHC quantification results
showed differences between apical and basal turns, we separated
the cochlea into two parts, the apical 50% and the basal 50%.
We measured the gene expression of the following anti-apoptotic
genes: Xiap (X-linked inhibitor of apoptosis), which belongs to
a family of apoptotic suppressor proteins, and Xaf1 (XIAP asso-
ciated factor 1), which binds to and counteracts the inhibitory
effect of a member of the IAP (inhibitor of apoptosis) protein
family. We also measured the expression levels of the following
pro-apoptotic genes: Casp3 and Casp9, which are members of
the caspase family and play central roles in the execution-phase
of apoptosis; Diablo, which encodes an IAP-binding protein; and
Htra2, which encodes a serine protease that induces apoptosis by
binding to the apoptosis inhibitory protein XIAP. All of the gene
expression data were normalized to the gene expression of P3
cochleae treated with saline. When compared to saline controls,
we found that the expression levels of the anti-apoptotic genes
Xiap and Xaf1 were significantly increased in neomycin-treated
cochleae from Groups 3 and 4 (p < 0.01 for both groups, n = 3)
and that the expression levels in the apical 50% of the cochlea
were slightly higher than in the basal 50%. There was no signif-
icant increase of Xiap or Xaf1 in neomycin-treated cochleae in
Groups 1 and 2 compared to their saline controls (Figure 3A),
and this indicated that Xiap might protect the cochlea from
neomycin-induced ototoxicity. Compared to saline controls, the
expression levels of the apoptotic genes Casp3, Casp9,Diablo, and
Htra2 were significantly increased in neomycin-treated cochleae
in Groups 2 and 3 (p < 0.01 for both groups, n = 3). The expres-
sion of Casp3 was also significantly increased in Groups 1 and
4 (p < 0.01 for both groups, n = 3), but the expression levels
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FIGURE 1 | Hearing loss in neomycin-treated WT mice. (A) ABR
measurements of WT mice 2 weeks after the last injection of neomycin or
saline (control). Neomycin or saline was injected once daily between P1 and
P7 (Group 1) (A1), P8 and P14 (Group 2) (A2), P15 and P21 (Group 3) (A3), or
P60 and P66 (Group 4) (A4). (B) ABR threshold shifts of neomycin-treated
samples compared to control. ∗∗p < 0.01 vs. control, n = 6–7.
of the other three apoptotic genes were only slightly increased
in Groups 1 and 4. In addition, the expression of apoptotic
genes in the apical 50% of the cochlea was slightly lower than
the basal 50% (Figure 3B). When compared among the four
groups, we found that the expression levels of the anti-apoptotic
genes Xiap and Xaf1 increased with age in saline controls. After
neomycin exposure, Xiap and Xaf1 expression levels in Groups 1
and 2 were similar to controls. In Group 4, however, the expres-
sion levels of Xiap and Xaf1 were significantly higher than all
other groups (Figure 3A). Because XIAP has protective effects
against apoptosis, one underlying cause of the sensitive period for
neomycin-induced ototoxicity might be low XIAP levels. We also
found that the expression levels of pro-apoptotic genes Casp3,
Casp9, Diablo, and Htra2 were significantly higher in Group 2—
in which neomycin was injected during the ototoxicity-sensitive
period of P8 to P14—than in all other groups (Figure 3B), and
this suggests that apoptotic factors are involved in the sensitive
period for neomycin-induced ototoxicity.
CASPASE-MEDIATED APOPTOSIS WAS INVOLVED IN THE SENSITIVE
PERIOD OF NEOMYCIN-INDUCED OTOTOXICITY
To confirm the involvement of caspase-mediated apoptosis in the
postnatal sensitive period for neomycin-induced ototoxicity in
vivo, we also divided the WT mice into four groups as described
above, injected them with neomycin or saline for 7 days, sacri-
ficed the mice at 1, 3, 5, or 7 days after the last injection, and
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FIGURE 2 | HC loss in neomycin-treated WT mice. (A) Representative
confocal images of myo7a immunofluorescence in cochlear whole mounts
of WT mice treated with neomycin or saline (control) once daily between
P1 and P7 (Group 1), P8 and P14 (Group 2), P15 and P21 (Group 3), or P60
and P66 (Group 4) and sacrificed 2 weeks after the last injection of
neomycin or saline. (B) Myo7a+ HC quantification in WT mice treated with
neomycin or saline (control) and sacrificed 2 weeks after the last injection
of neomycin or saline. Scale Bar in A = 10μm.
stained the cochleae with cleaved-caspase-3 andmyo7a antibodies
(Figure S1A). We found that the number of HCs kept decreas-
ing from day 1 to 7 in all neomycin-treated groups. At each time
point, there was a significant difference between Group 2 and
the three other neomycin-treated groups (p < 0.01, Figure S1).
Moreover, the number of caspase-3+ cells was greatest at 3 days
following the neomycin injection (Figures 4B1, S1A), and this
was the time-point chosen for further analysis. At 3 days after
neomycin or saline treatment, no caspase-3+ cells were observed
in any of the three turns of the control cochleae treated with
saline, and this was consistent with a previous report (Kaiser et al.,
2008). Among the four groups with neomycin treatment, Group 2
had significantly more caspase-3+ and caspase-3+/myo7a+ cells
in the apical turn of cochlea (17.00 ± 4.58 cells and 7.67 ± 2.10
cells per cochlear apical turn, respectively, p < 0.01, n = 3). The
other three groups had very few caspase-3+ cells and almost no
caspase-3+/myo7a+ cells in the apical turn (Figures 4A,B2,B3).
This result suggested that caspase-mediated apoptosis is involved
in the neomycin-induced ototoxicity of the apical turn during the
sensitive period. In middle and basal turns, all four groups had
significantlymore caspase-3+ and caspase-3+/myo7a+ cells than
the control groups (p < 0.01, n = 3), but Group 2 had signifi-
cantly more caspase-3+ cells (31.67 ± 3.51 cells and 18.33 ± 1.38
cells per cochlear middle and basal turn, respectively) compared
to Groups 1, 3, and 4 (17.33 ± 5.86 cells and 10.67 ± 0.58 cells,
17.33 ± 3.52 cells and 11.33 ± 2.31 cells, 8.33 ± 1.52 cells and
4.00 ± 2.13 cells per cochlear middle and basal turn per group,
respectively, p < 0.01, n = 3) and Group 2 had more caspase-
3+/myo7a+ cells (11.67 ± 1.53 cells and 5.67 ± 1.53 cells per
cochlear middle and basal turn, respectively) compared to Groups
1, 3, and 4 (3.00 ± 1.12 cells and 1.67 ± 0.58 cells, 2.67 ± 0.58
cells and 2.00 ± 1.21 cells, 2.00 ± 0.67 cells and 1.33 ± 0.58
cells per cochlear middle and basal turns per group, respectively,
p < 0.01, n = 3) (Figures 4A,B2,B3). This result suggested that
caspase-mediated apoptosis is also involved in the postnatal sen-
sitive period of neomycin-induced ototoxicity inmiddle and basal
turns.
XIAP OVEREXPRESSION ATTENUATED NEOMYCIN-INDUCED HC LOSS
IN THE APICAL TURN DURING THE OTOTOXICITY-SENSITIVE PERIOD
To further investigate whether apoptotic factors are involved in
the sensitive period to neomycin-induced ototoxicity in the api-
cal turn, we took advantage of genetic methods to inhibit the
apoptotic factors in neomycin-treated mice. Here we used trans-
genic XIAP overexpression mice, in which the coding sequence
of XIAP is under the control of a ubiquitin promoter (ubX-
IAP) (Wang et al., 2010). In this experiment, we injected WT or
ubXIAP overexpression mice with neomycin or saline during the
ototoxicity-sensitive period (Group 2, P8–P14). ABR thresholds
were measured from six mice in each group at P30, and HC loss
in all three cochlear turns was evaluated from 4–5 cochleae in each
group at P30 (Figure 5A). In the neomycin-treated groups, ABR
thresholds were significantly decreased at 8 kHz in the XIAP over-
expression mice compared to WT mice (p < 0.01, n = 6). There
was a slight decrease at 16 kHz (p < 0.05, n = 6), but no sig-
nificant difference was detected at 24 and 32 kHz. There was no
ABR threshold increase in the XIAP overexpression mice without
neomycin injection (Figure 5A2).
Moreover, in the neomycin-treated groups, there was almost
no HC loss in the apical turn of the cochleae from XIAP overex-
pression mice, and this demonstrated that XIAP overexpression
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FIGURE 3 | Apoptosis-related gene expression in neomycin-treated WT
mice. (A,B) mRNA expression of the anti-apoptotic genes Xiap (A1) and Xaf1
(A2) and the pro-apoptotic genes Casp3 (B1), Casp9 (B2), Diablo (B3), and
Htra2 (B4) in the apical 50% and basal 50% of the cochleae in WT mice
sacrificed 3 days after the last injection of neomycin or saline (control).
Neomycin or saline was injected between P1 and P7 (Group 1), P8 and P14
(Group 2), P15 and P21 (Group 3), or P60 and P66 (Group 4). ∗p < 0.05,
∗∗p < 0.01 vs. control, n = 3.
almost completely prevented the neomycin-induced HC loss in
the apical turn during the ototoxicity-sensitive period. HC loss
was slightly attenuated in middle and basal turns in XIAP over-
expression mice. There was no HC loss in XIAP overexpression
mice without neomycin treatment (Figures 5A1,A3).
We further examined the cleaved-caspase-3 expression in
neomycin-treated XIAP overexpressing mice. In this experiment,
we injected WT or ubXIAP mice with neomycin or saline from
P8 to P14, sacrificed the mice at 3 days after the last injection, and
stained the cochleae with cleaved-caspase-3 andmyo7a antibodies
(Figure 5B1). We found that when treated with neomycin, XIAP
overexpression mice had only a very small number of caspase-
3+ cells and no caspase-3+/myo7a+ HCs in the apical turn.
They also had significantly fewer caspase-3+ cells and caspase-
3+/myo7a+ HCs in the middle and basal turns compared to
the WT mice (Figures 5B2,B3, p < 0.05, n = 3). Together, these
results suggest that when neomycin was injected during the
ototoxicity-sensitive period, HC loss in the apical turn was pri-
marily caused by the hypersensitivity to neomycin-induced oto-
toxicity (Figure 2). XIAP overexpression significantly reduced
hearing loss and HC loss in the apical turn, but only partially pre-
vented the HC loss in the middle and basal turns (Figure 5). We
Frontiers in Cellular Neuroscience www.frontiersin.org September 2014 | Volume 8 | Article 248 | 6
Sun et al. XIAP and neomycin-induced hearing loss
FIGURE 4 | Caspase-3 expression after neomycin treatment. (A)
Representative confocal images of all three turns of the cochlea stained with
myo7a and cleaved caspase-3 in WT mice sacrificed 3 days after the last
injection of neomycin or saline (control). Neomycin or saline was injected
between P1 and P7 (Group 1), P8 and P14 (Group 2), P15 and P21 (Group
3), or P60 and P66 (Group 4). (B1) The number of caspase-3+ cells in the
whole cochlea of WT mice treated with neomycin or saline (control)
between P1 and P7 (Group 1), P8 and P14 (Group 2), P15 and P21 (Group
3), or P60 and P66 (Group 4) and sacrificed 1, 3, 5, or 7 days after neomycin
or saline treatment. (B2,B3) The number of caspase-3+ cells (B2) and
caspase-3+/myo7a+ cells (B3) in the three cochlear turns of WT mice
treated with neomycin or saline (control) between P1 and P7 (Group 1), P8
and P14 (Group 2), P15 and P21 (Group 3), or P60 and P66 (Group 4) and
sacrificed 3 days after the last injection of neomycin or saline treatment.
∗∗p < 0.01 vs. control and #p < 0.05, ##p < 0.01, vs. Group 2, n = 3. Scale
bar in A = 10μm.
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FIGURE 5 | Hearing loss and HC loss in neomycin-treated XIAP
overexpression mice. (A1) Representative confocal images of myo7a
immunofluorescence in cochlear whole mounts of XIAP overexpression and
WTmice treated with neomycin or saline (control) between P8 and P14 (Group
2) and sacrificed at P30. ABR measurement (A2) and myo7a+ HC
quantification (A3) of P30 XIAP overexpression and WT mice treated with
neomycin or saline (control) between P8 and P14. (B1)Representative confocal
images of myo7a and cleaved-caspase-3 immunofluorescence in cochlear
whole mounts of XIAP overexpression and WT mice treated with neomycin or
saline (control) between P8 and P14 (Group 2) and sacrificed at P17. (B2,B3)
The quantification of caspase-3+ cells (B2) and caspase-3+/myo7a+ cells (B3)
in the three cochlear turns of XIAP overexpression and WT mice treated with
neomycin or saline (control) between P8 and P14 (Group 2) and sacrificed at
P17. ∗p < 0.05, ∗∗p < 0.01 vs. WT neomycin, n = 3. Scale bar in A = 10μm.
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thus conclude that apoptotic factors are involved in the sensitive
period of neomycin-induced ototoxicity in the apical turn of the
cochlea.
DISCUSSION
Aminoglycosides are effective against aerobic gram-negative
infections and are widely used to treat tuberculosis in people in
developing countries and to treat life-threatening bacterial infec-
tions in premature infants across the world. All aminoglycosides
have the potential for nephrotoxicity, ototoxicity, neuromuscu-
lar blockade, allergic reactions, and hematotoxicity, and these
adverse effects limit the clinical use of aminoglycoside antibiotics.
Aminoglycoside ototoxicity is typically associated with bilateral
sensorineural hearing loss and tinnitus (Nadol, 1993), yet there
have been only a few in vivo investigations of aminoglycoside
ototoxicity in mammalian development.
Previous reports indicated that aminoglycoside-induced
cochlear HC loss is more severe in neonatal mice than in adults,
and this led to the development of the concept of an ototoxicity-
sensitive period (Chen and Aberdeen, 1981; Chen and Saunders,
1983; Eggermont, 1986; Henley and Rybak, 1993, 1995; Henley
et al., 1996). However the mechanism underlying this sensitive
period has not been elucidated. In our experiments, we injected
neomycin during the four different ages of P1–P7, P8–P14, P15–
P21, and P60–P66 and found that all groups of C57BL/6J WT
mice were sensitive to neomycin-induced hearing loss at high fre-
quencies. However, at low frequencies only the P8–P14 group was
sensitive to neomycin-induced hearing loss and only that group
had significant HC loss in the apical turn. Taken together, these
results suggest that HC loss in the apical turn is primarily caused
by hypersensitivity to neomycin-induced ototoxicity during the
sensitive period of P8 to P14.
Pharmacokinetics experiments have shown that aminoglyco-
sides have a longer serum half-life and a lower serum clearance
rate in neonates than in adults, and this might result in increased
risk of permanent ototoxic damage in neonates (Henley and
Rybak, 1993; Berard et al., 1994; Scaglione et al., 1995). In
addition to metabolic and anatomic factors, animal models of
aminoglycoside-induced ototoxicity have also indicated hyper-
sensitivity of neonates to ototoxic drugs compared to adults, but
the underlying mechanisms behind this hypersensitivity remain
unclear. When aminoglycoside antibiotics are taken up into sen-
sory HCs and transported to endosomes and lysosomes, lysoso-
mal phospholipidosis is followed by lysosomal rupture and this
lead to the release of aminoglycosides into the cytoplasm and
impairment of mitochondrial respiration (Chen et al., 1996).
This in turn can lead to several different biochemical events.
(1) Complexes can form with transition metals (iron and cop-
per), and these promote the formation of superoxide radicals
such as hydroxyls. These in turn can trigger lipid peroxida-
tion that progressively inhibits metabolic activities (Guo et al.,
2001). (2) There is increased calcium influx into cells resulting
in calcium overload. (3) Caspase-mediated apoptotic cascades
are initiated (Forge, 1985; Li et al., 1995; Nakagawa et al., 1997;
Cunningham et al., 2002). (4) JNK-mediated cell apoptosis is
initiated (Ylikoski et al., 2002; Sugahara et al., 2006). (5) The
permeability of the mitochondria changes, and this leads to the
release of apoptosis-inducing factor and endonuclease G, both
of which can then move into the nucleus and activate caspase-
independent pathways that can lead to apoptosis-like features in
cells (Jiang et al., 2006).
In our study, HC damage in the basal turn of the cochlea was
much more severe than in the apical turn, and this is correlated
with previous reports that outer HCs from the basal turn are
more susceptible to damage than outer HCs in the apical turn
(Sha et al., 2001; Jensen-Smith et al., 2012). The underlying cause
for this phenotype might be the following: (1) the cochlear blood
flow moves more quickly in the basal turn and this results in
higher concentrations of drugs in the basal turn; (2) the outer
HCs of the basal turn are smaller and contain more mitochondria
and are thus more susceptible to damage; and (3) the distribution
and activity of drug transporters in basal and apical outer HCs is
different (Ding and Salvi, 2007).
To investigate the underlying mechanism behind the hyper-
sensitivity to neomycin-induced ototoxicity in the apical turn
during the sensitive period, we measured the expression level
of apoptosis-related genes when neomycin was injected during
different periods. We found that the expression levels of the apop-
totic factors Casp3, Casp9, Diablo, and Htra2 were significantly
higher when neomycin was injected during the sensitive period
compared to other periods, and this suggested that apoptotic fac-
tors are involved in the sensitive period for neomycin-induced
ototoxicity.
We then investigated the possible molecular biological mech-
anism leading to the ototoxicity-sensitive period. XIAP has the
most potent anti-apoptotic effects. It contains a single C-terminal
RING domain and three tandem baculoviral IAP repeat (BIR)
domains. BIR1 and BIR2 have been shown to inhibit caspase-3
and caspase-7 activation (Suzuki et al., 2001), and the caspase-
9 inhibitory activity of XIAP has been localized to the BIR3-
RING domain (Srinivasula et al., 2001; Shiozaki et al., 2003;
Zou et al., 2003). It has been well established that overex-
pression of XIAP can protect against apoptosis. There is also
evidence that AAV-mediated delivery of XIAP protects against
cisplatin ototoxicity (Cooper et al., 2006). XIAP overexpression
has been demonstrated to prevent neuronal death in mod-
els of transient cerebral ischemia and Parkinson’s disease (Xu
et al., 1999; Ishigaki et al., 2002; Crocker et al., 2003; Trapp
et al., 2003). The same ubiquitous XIAP overexpression mice
used in this study also exhibit later onset of presbycusis and an
insensitivity to noise-induced hearing loss (Wang et al., 2010,
2011).
To further investigate the role of XIAP in the sensitive period
for neomycin-induced ototoxicity, we injected neomycin into
transgenic XIAP overexpression mice during the sensitive period.
ABR data showed that XIAP overexpression protected against
hearing loss from neomycin-induced ototoxicity at 8 kHz, but the
protective effect was not significant at 16, 24, or 32 kHz. When we
quantified the number of remaining HCs, we found that XIAP
overexpression almost completely protected against HC loss in
the apical turn, but this protective effect was not significant in the
middle and basal turns. Thus, there might be other non-apoptotic
mechanisms involved in HC death in the middle and basal turns
as we discussed previously.
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All of these results showed that when neomycin was injected
during the ototoxicity-sensitive period HC loss in the apical turn
was primarily caused by hypersensitivity to neomycin-induced
ototoxicity and that XIAP overexpression almost completely pre-
vented this HC loss in the apical turn. We thus conclude that
apoptotic factors are involved in the apical turn during the
ototoxicity-sensitive period.
In contrast to the protective effect described above, XIAP over-
expression failed to protect against hearing loss or against HC loss
in middle and basal turns of the cochlea. Our qPCR data showed
that Casp3 expression was significantly elevated in the entire
cochlea when neomycin was injected during the ototoxicity-
sensitive period, but overexpression of XIAP—the most potent
caspase inhibitor—was only able to partially prevent HC loss in
the middle and basal turns. One possible reason for this limited
protection is that neomycin-induced ototoxicity in the middle
and basal turns is not mediated by the classical caspase-induced
apoptosis pathway or the JNK signaling pathway, but rather by
caspase-independent apoptosis pathways (Jiang et al., 2006) or
by necrosis due to the chronic nature of drug administration
(Wang and Li, 2000). It is also possible that ubiquitous over-
expression of human XIAP in transgenic mice might not be
sufficient to protect against the neomycin-induced HC loss in
the middle and basal turns where neomycin concentrations are
higher.
In summary, our results show that XIAP overexpression can
successfully prevent neomycin-induced hearing loss and HC loss
in the apical turn of the cochlea during the sensitive period. These
results also provide in vivo evidence that apoptotic factors are
involved in the sensitive period of neomycin-induced ototoxicity.
Overexpression of XIAP, therefore, might serve as a novel ther-
apeutic target for reducing aminoglycoside-induced HC damage
and hearing loss.
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Figure S1 | Caspase-3 expression in WT mice after neomycin treatment.
(A) Representative confocal images of myo7a immunofluorescence in
cochlear whole mounts of WT mice sacrificed at 1, 3, 5, or 7 days after the
last injection of neomycin or saline (control). Neomycin or saline was
injected between P1 and P7 (Group 1), P8 and P14 (Group 2), P15 and P21
(Group 3), or P60 and P66 (Group 4). (B) Myo7a+ HC quantification in WT
mice treated with neomycin or saline (control) between P1 and P7 (Group
1), P8 and P14 (Group 2), P15 and P21 (Group 3), or P60 and P66 (Group 4)
and sacrificed at 1, 3, 5, or 7 days after the last injection of neomycin or
saline. ∗∗p < 0.01 vs. control and #p < 0.05, ##p < 0.01 vs. Group 2,
n = 3. Scale bar in A = 10μm.
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